Last reviewed · How we verify

standard IV treatment for headache

HCA Florida North Florida Hospital · Phase 3 active Small molecule

Sumatriptan works by binding to serotonin receptors, specifically 5-HT1B and 5-HT1D receptors, to induce vasoconstriction and inhibit pro-inflammatory neuropeptide release.

Sumatriptan works by binding to serotonin receptors, specifically 5-HT1B and 5-HT1D receptors, to induce vasoconstriction and inhibit pro-inflammatory neuropeptide release. Used for Acute treatment of migraine attacks with or without aura, Prevention of migraine headaches.

At a glance

Generic namestandard IV treatment for headache
SponsorHCA Florida North Florida Hospital
Drug classTriptan
Target5-HT1B, 5-HT1D
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

This action leads to the relief of migraine headache symptoms. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of pro-inflammatory neuropeptide release and the induction of vasoconstriction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: